SEC Form 4 · accession 0000899243-18-018328

· DNTH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 25, 2018

Accepted (ET)

Jun 27, 2018 · 4:28 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001690585

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jun 25, 2018	C	4,746,876	—	A	4,843,625	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F1,F2	—	Jun 25, 2018	C	12,061,496	D	—	—	Common Stock	4,667,797	0	I
Series B Preferred Stock^F1,F2	—	Jun 25, 2018	C	204,339	D	—	—	Common Stock	79,079	0	I

F1The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.
F2The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.